Muscle Pharm Corp. (MSLP.OB) previously announced a multi-year partnership with the World Bodybuilding and Fitness Federation (WBFF) that will place the company as the title sponsor of the World Famous WBFF through 2014.
The partnership begins in 2011 and MusclePharm will work closely with the WBFF and its President and CEO, Paul Dillett, who is widely considered one of the greatest bodybuilders in the sport’s history. Dillett, recognized as Canada’s greatest bodybuilder, won numerous bodybuilding titles throughout his illustrious career, and is often regarded as having one of the sport’s most recognizable physiques.
MusclePharm’s President, Cory Gregory, commented, “We are very excited to partner with the WBFF. We believe this relationship will expand our brand by introducing our nutritional supplements, which are 100% free of any banned substances, to a new market.”
MusclePharm products are created through an advanced six-stage research protocol involving the expertise of top nutritional scientists and field tested by more than 100 elite professional athletes from various sports including the NFL, MMA, and MLB.
For more information about this company please visit http://www.musclepharm.com
Power3 Medical Products, Inc. (PWRM.OB) previously signed a definitive agreement to acquire all of the stock of Rozetta-Cell Life Sciences, Inc., a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy.
PWRM plans to effectuate the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into PWRM, with PWRM remaining as the surviving company in the merger. The acquisition of Rozetta-Cell is expected to be completed in November 2010.
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s and ALS diseases, for which it is currently engaged in Phase II clinical trials. The tests are designed to analyze an individual’s proteins to detect the presence of disease, a patient’s disease progression, a patient’s response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.
For more information about this company please visit http://www.power3medical.com
Solitario Exploration & Royalty Corp. (AMEX:XPL) reported that Solitario has initiated core drilling on the advanced Mt. Hamilton gold project situated at the southern end of the prolific Battle Mountain gold trend in eastern Nevada. Two core rigs are now drilling as part of a twelve-hole program to provide feasibility-level geotechnical, hydro-geologic and infill resource information for the feasibility study that is now underway. In addition, Solitario made the $300,000 advanced royalty payment to the underlying owners of the Mt. Hamilton lease as prescribed in the binding Letter of Intent (“LOI”) to joint venture the Mt. Hamilton gold project. Solitario can earn up to an 80% interest in the property by completing a bankable feasibility study and making future property and royalty payments.
Solitario Exploration & Royalty Corp., an exploration stage company, engages in the exploration and acquisition of precious metals and base metals in Brazil, Mexico, Peru, and Bolivia.
CAMAC Energy Inc. (AMEX:CAK) reported a net loss of $188.6 million, or $1.32 per diluted share for the three months ended September 30, 2010. This includes a non-cash impairment charge of $186.2 million, or $1.30 per diluted share due to a downward revision of proved reserves at the Oyo Field. Excluding this non-cash charge, CAMAC Energy had a net loss of $2.3 million, or $0.02 per diluted share, for the three months ended September 30, 2010, compared with a net loss of $2.6 million, or $0.06 per diluted share, for the same period in 2009. Included in its third quarter results, CAMAC Energy plans to issue a summary of an updated independent reserves report with its Form 10-Q for the quarter that shows the Company has total estimated net proved reserves of 5.4 million barrels, compared to the 9.4 million barrels estimated in the 2008 reserve report the Company inherited through the April 2010 acquisition of its Oyo Field interests, all of which belong to the Company’s interest in the Oyo Field.
CAMAC Energy Inc. engages in the exploration, development, production and distribution of oil and gas. The company was founded in 2010 and is based in Hartsdale, New York. CAMAC Energy Inc. operates as a subsidiary of CAMAC International Corporation.
Cardium Therapeutics Inc. (AMEX:CXM) previously announced a co-development and strategic licensing agreement with BioZone Laboratories, Inc. (”BioZone”) for the formulation, manufacture and licensing of a portfolio of up to 20 aesthetics, advanced skin care formulations and other products for Cardium’s MedPodium™ product line. Under terms of the agreement, Cardium will identify a line of products applying BioZone technology such as that incorporated into its QuSome™, Inflacin™, LipoCeutical™, LipoSpray™ and other formulation and delivery technologies.
Cardium Therapeutics, Inc. focuses on the acquisition and development of biomedical product opportunities and businesses that have the potential to address unmet medical needs, and definable pathways to partnering, commercialization, and other monetizations.
CRWESelect, a stock highlight publication is pleased to alert investors of stocks on the move.
Sign Up for our Free Stock Newsletter at http://www.crweselect.com/signup
PLEASE BE SURE TO VISIT CRWESELECT.NING.COM
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer( http://crweselect.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (PWRM.OB). Crown Equity Holdings Inc. (CRWE.OB) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for 30 (thirty) days of advertising for MusclePharm Corporation (MSLP.OB).